Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Non-small Cell Lung Cancer
Related studies linked through entity extraction aliases.
Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC
- Status
- COMPLETED
- Phase
- PHASE2
Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge
- Status
- RECRUITING
- Phase
- PHASE2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- Status
- RECRUITING
- Phase
- PHASE2
eRAPID: Online Symptom Reporting in Lung Cancer
- Status
- COMPLETED
- Phase
- NA
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
- Status
- RECRUITING
- Phase
- N/A
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial
- Status
- RECRUITING
- Phase
- N/A
Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC
- Status
- RECRUITING
- Phase
- PHASE2
Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)
- Status
- COMPLETED
- Phase
- PHASE1
Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
- Status
- RECRUITING
- Phase
- PHASE2
Bioimaging Study of 89Zr-M7824 in NSCLC
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Analysis of Driver Gene Mutation in Early Stage Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- N/A